Overview

Treatment Trial of Alveolar Echinococcosis

Status:
COMPLETED
Trial end date:
2023-07-31
Target enrollment:
Participant gender:
Summary
A new focus of subjects with lesions of alveolar echinococcosis caused by Echinococcus multilocularis has been found south of Gulcha in Osh province in Kyrgyzstan by an ultrasound surveillance. Prevalence of infections is approximately 6%. Most lesions are small. Current scientific evidence suggests that in the absence of treatment, alveolar echinococcosis has a case fatality rate approaching 100% within 10-15 years of infection. Albendazole is known to be effective as a parasitostatic treatment to prolong the life of subjects with this disease, possibly up to normal life expectancy with prolonged treatment. The trial will be a case control study to evaluate the treatment of subjects with early stage alveolar echinococcosis and the progression of disease.
Phase:
PHASE2
Details
Lead Sponsor:
Ministry of Health, Kyrgyzstan
Collaborator:
University of Zurich